Selected Publications
1. Identified the first molecular mechanism of resistance to TB drug isoniazid (INH)
Zhang, Y., Heym, B., Allen, B., Young, D., and Cole, S. (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. [Comment] Nature (London) 358: 591-593.
Zhang, Y., Garbe, T., and Young, D. (1993) Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol. 8: 521-524.
Zhang, Y. (2004). Isoniazid, In William N. Rom and Stuart Garay, ed, TUBERCULOSIS – 2nd Ed, Chapter 49, pp739-758, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York.
2. Identified the molecular mechanisms of resistance and action for the unique persister drug pyrazinamide (PZA):
Scorpio, A. and Zhang, Y. (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus [Comment]. Nature Med 2:662-667.
Scorpio, A., Lindholm-Levy, P., Heifets, L., Gilman, R., Siddiqi, S., Cynamon, M., and Zhang, Y. (1997) Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agent Chemother 41: 540-543.
Zhang, Y., Scorpio, A., Nikaido, H., and Sun, Z.H. (1999). Role of acid pH and deficient efflux of pyrazinoic acid in the unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049.
Cheng, S.J., Thibert, L., Sanchez, T., Heifets, L., and Zhang, Y. (2000) pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a mono-resistant strain in Quebec Canada. Antimicrob. Agents Chemother44:528-532.
Zhang, Y., Permar, S., and Sun, Z. (2002). Conditions that may affect the results of Mycobacterium tuberculosis susceptibility testing to pyrazinamide [Comment]. J. Med. Microbiol. 51:42-49
Zhang, Y., M. M. Wade, A. Scorpio, H. Zhang, Z. Sun (2003) Mode of Action of Pyrazinamide: Disruption of Mycobacterium tuberculosis Membrane Transport and Energetics by Pyrazinoic Acid. J. Antimicrob. Chemother. 52: 790-795.
Wanliang Shi, Xuelian Zhang, Xin Jiang, Haiming Yuan, Jongseok Lee, Clifton E. Barry, 3rd, Honghai Wang, Wenhong Zhang, Ying Zhang (2011). Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis [Comment]. Science, 333:1630-1632.
3. Identified new persister mechanisms in bacterial persistence and L-form bacteria
Li Y and Zhang Y. (2007). PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob. Agents Chemother. 51:2092-9
Shi W and Zhang Y. (2010). PhoY2 but not PhoY1 is the PhoU Homolog Involved in Persisters in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65:1237-42
Chao Ma, Shuzhen Sim, and Wanliang Shi and Ying Zhang. (2010). SucB and UbiF Are Involved in Persister Formation and Tolerance to Multiple Antibiotics and Stresses in Escherichia coli. FEMS Microbiol Lett. 303:33-40.
William Glover, Yanqin Yang, Ying Zhang. (2009). Insights into the Molecular Basis of L-Form Formation and Survival in Escherichia coli. PLoS ONE. Oct 6;4(10):e7316.
Sun, Z., and Zhang, Y. (1999). Spent culture supernatant of Mycobacterium tuberculosis strain H37Ra improved the viability of aged cultures and allowed small inocula to initiate growth in liquid culture. J. Bacteriol. 181:7626-7628.
Zhang, Y., Yang, Y-P, Woods, A., Cotter, R., and Sun, Z-H. (2001) Resuscitation of dormant tubercle bacilli by phospholipids or specific peptides. Biochem. Biophysic. Res Comm 284:542-547.
Zhang, Y. (2004). Persistent and Dormant Tubercle Bacilli and Latent Tuberculosis. Frontiers in Bioscience. 9: 1136-1156.
Zhang, Y, Yew, WW and Michael Barer. (2012). Targeting tuberculosis persisters for improved control. Antimicrob. Agents Chemother. 56: 2223-2230.
4. TB Treatment and New Drug Discovery:
Sun, Z. and Zhang, Y. (1999). Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuberc. Lung Dis. 79:319-320.
Zhang, Y., H. Zhang, and Z. Sun (2003) Susceptibility of Mycobacterium tuberculosis to weak acids. J. Antimicrob. Chemother. 52:56-60.
Byrne ST, Denkin SM, Gu P, Nuermberger E and Zhang Y. (2007). Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J. Med. Microbiol. 56:1047-51.
Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, Sullivan D, Liu JO, Zhang Y. (2007). Pyrrolidine dithiocarbamate (PDTC) and diethyldithiocarbamate (DETC) are against growing and non-growing persister Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:4495-7.
Byrne ST, Denkin SM, Zhang Y. (2007). Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59: 313-316.
Zhang, Y. (2005). The Magic Bullets and Tuberculosis Drug Targets. Ann. Rev. Pharmacol. Toxicol. 45: 529-564
Zhang, Y. (2007). Advances in the Treatment of Tuberculosis. Clin. Pharmacol. Therapeutics 82:595-600.
Zhang, Y (2012). Drug Resistant and Persistent Tuberculosis: Mechanisms And Drug Development. Chapter 22, In “ANTIBIOTIC DISCOVERY AND DEVELOPMENT”, T.J Dougherty, M. J Pucci (ed), Springer. Vol. 1, 719-749.
5. TB Pathogenesis, Immunology and Vaccines
Zheng H, Lu L, Wang B, Pu S, Zhang X, Zhu G, Shi W, Zhang L, Wang H, Wang S, Zhao G, Zhang Y. (2008). Comparative Genomic Analysis of Attenuated Mycobacterium tuberculosis Strain H37Ra versus its Virulent Counterpart H37Rv: Insight into the Basis of Virulence Attenuation. PLoS ONE, 3(6): e2375.
Guoping Zhang, Bingdong Zhu, Wanliang Shi, Mingzhu Wang, Zejiao Da, Ying Zhang. (2010). Evaluation of mycobacterial virulence using rabbit skin liquefaction model. Virulence, 1 (no.3): 1-8
Zhang, Y. (2008). Immunopathogenesis of Tuberculosis: Implications for Vaccine Development. Respirology, 13: S81-S87.
Dheda K, Schwander SK, Zhu B and Zhang Y. (2010). The Immunology of Tuberculosis: From Bench to Bedside. RESPIROLOGY. 15: 433-450
6. TB Drug Resistance and Detection
Wade, M.M., D. Volohkov, M. Peredelchuk, V. Chizhikov, and Y. Zhang (2004) Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn. Microbiol. Infect. Dis. 49: 89-97.
Zhang, Y., and Telenti, A. (2000). Genetics of Drug Resistance in Mycobacterium tuberculosis. In “Molecular Genetics of Mycobacteria”, pp235-254, edited by G. Hatfull and W.R. Jacobs, ASM Press, Washington D.C.
Zhang, Y and Jacobs, WR, Jr (2008). Mechanisms of Drug Action, Drug Resistance and Drug Tolerance in Mycobacterium tuberculosis: Expected Phenotypes from Evolutionary Pressures from a Highly Successful Pathogen. In Handbook of Tuberculosis, Volume 1, S.H.E. Kaufmann and E. Rubin, Ed, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, p323-378.
Zhang, Y. and Yew, W.W. (2009). Mechanisms of Drug Resistance in Mycobacterium tuberculosis,State of the Art [Editorial comment]. Int J Tuberc Lung Dis, 13:1320-1330.
Min Zhong, Xi-yan Zhang, Yiwei Wang, Chun-zhi Zhang, Gang Chen, Pin-pin Hu, Miao Li, Bingdong Zhu, Wenhong Zhang, Ying Zhang. An interesting case of rifampin-dependent/enhanced MDR-TB. (2010). Int J Tuberc Lung Dis. 14: 40-44.
7. Cancer Stem Cell Pathways and Compounds
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 104: 16158-16163.
Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. (2008). NF-kB pathway inhibitors preferentially inhibit breast cancer stem cells. Breast Cancer Research and Treatment, 111:419-27 [Epub ahead of print]
Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Yin D, and Zhang Y. (2009). Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Research and Treatment, 115: 269-277 [Epub ahead of print, May 28, 2008]
Zhou, J and Zhang, Y. (2008). Cancer Stem Cells: Models, Mechanisms, and Implications for Improved Treatment. Cell Cycle, 7: 1360-1370.
Zhou, J and Zhang, Y. (2009). Preclinical development of cancer stem cell drugs. Expert Opinion on Drug Discovery. 4: 741-752.
